Illustration with heart beat
SynCardia Systems files Form S-1 for IPO
SynCardia Systems, a developer and manufacturer of temporary implantable artificial hearts, filed on Monday with the SEC to raise up to $40 million in an initial public offering.
Based in Tucson, Arizona, SynCardia Systems, Inc. is the manufacturer of the world’s first and only FDA, Health Canada and CE approved Total Artificial Heart for use as a bridge to transplant for people suffering from end-stage biventricular heart failure in which both ventricles can no longer pump enough blood for a person to survive.
More than 1,440 implants of the SynCardia Total Artificial Heart account for over 465 patient years of life on the device. Since January 2010 more than 600 SynCardia Hearts have been implanted.
The youngest patient to receive a SynCardia Heart was 9 years old; the oldest was 80 years old. The longest a patient has lived with a SynCardia Heart was nearly four years (1,374 days) before receiving a successful donor heart transplant.
SynCardia Systems also manufactures the Freedom® portable driver, which powers the SynCardia Heart while allowing clinically stable patients to be discharged from the hospital to live at home and in their communities. The Freedom® portable driver has been used by more than 220 patients, accounting for over 140 years of patient support.
The FDA on June 26, 2014 approved the use of the Freedom® portable driver for all clinically stable U.S. patients on the SynCardia Total Artificial Heart. The Freedom® portable driver also is approved by Health Canada and has the CE Mark for use in Europe.
SynCardia is conducting an FDA-approved clinical study on the effectiveness of the SynCardia Total Artificial Heart and the Freedom® portable driver for use as destination therapy, also known as permanent use, in the United States.
According to Renaissance Capital: “The Tucson, AZ-based company, which was founded in 2001 and booked $18 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol TAHT. Roth Capital is the sole bookrunner on the deal. No pricing terms were disclosed. “